<?xml version="1.0" encoding="UTF-8"?>
<html><body class="spl" id="spl">
<div class="DocumentTitle"><p class="DocumentTitle"><strong>ULTRESA- pancrelipase lipase, pancrelipase protease and pancrelipase amylaseÂ capsule, delayed releaseÂ </strong><br>Aptalis Pharma US, Inc<br></p></div>
<div id="Highlights" class="Highlights"><table cellspacing="5" cellpadding="5" width="100%" style="table-layout:fixed"><tr><td align="left" valign="top"><div>
<h1>HIGHLIGHTS OF PRESCRIBING INFORMATION</h1>
<div class="HighlightsDisclaimer">These highlights do not include all the information needed to use ULTRESA safely and effectively. See full prescribing information for ULTRESA.<br>ULTRESA (pancrelipase) delayed-release capsules, for oral use<br>Initial U.S. Approval: 2012 </div>
<div></div>
<div class="HighlightSection">
<h1 class="Highlights"><span>INDICATIONS AND USAGE</span></h1>
<div><p class="Highlighta">ULTRESA<span class="Sup">Â®</span> is a combination of porcine-derived lipases, proteases, and amylases indicated for the treatment of exocrine <span class="product-label-link" type="condition" conceptid="4243784" conceptname="Pancreatic insufficiency">pancreatic insufficiency</span> due to <span class="product-label-link" type="condition" conceptid="441267" conceptname="Cystic fibrosis">cystic fibrosis</span> or other conditions. (<a href="#section_1">1</a>) </p></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>DOSAGE AND ADMINISTRATION</span></h1>
<div>
<p class="Highlighta">ULTRESA is not interchangeable with any other pancrelipase product. (<a href="#section_2">2</a>) </p>
<p class="Highlighta"><span class="Underline"><span class="Italics">Administration</span></span> </p>
<ul><li>ULTRESA should be swallowed whole. Do not crush or chew the capsules and the capsule contents. For children or patients unable to swallow intact capsules, the contents may be sprinkled on soft acidic food with pH of 4.5 or less such as applesauce or yogurt. (<a href="#section_2_1">2.1</a>)</li></ul>
<p class="Highlighta"><span class="Underline"><span class="Italics">Infants (up to 12 months)</span></span> </p>
<ul>
<li>Infants may be given 4,000 lipase units per 120 mL of formula or per breast-feeding. (<a href="#section_2_2">2.2</a>)</li>
<li>Do not mix ULTRESA capsule contents directly into formula or breast milk prior to administration. (<a href="#section_2_1">2.1</a>)</li>
</ul>
<p class="Highlighta"><span class="Underline"><span class="Italics">Children Older than 12 Months and Younger than 4 Years</span></span> </p>
<ul><li>Begin with 1,000 lipase units/kg of body weight per meal to a maximum of 2,500 lipase units/kg of body weight per meal (or less than or equal to 10,000 lipase units/kg of body weight per day), or less than 4,000 lipase units/g fat ingested per day. (<a href="#section_2_2">2.2</a>)</li></ul>
<p class="Highlighta"><span class="Underline"><span class="Italics">Children 4 Years and Older and Adults</span></span> </p>
<ul><li>Begin with 500 lipase units/kg of body weight per meal to a maximum of 2,500 lipase units/kg of body weight per meal (or less than or equal to 10,000 lipase units/kg of body weight per day), or less than 4,000 lipase units/g fat ingested per day. (<a href="#section_2_2">2.2</a>)</li></ul>
<p class="Highlighta"><span class="Underline"><span class="Italics">Limitations on Dosing</span></span> </p>
<ul><li>Dosing should not exceed the recommended maximum dosage set forth by the <span class="product-label-link" type="condition" conceptid="441267" conceptname="Cystic fibrosis">Cystic Fibrosis</span> Foundation Consensus Conferences Guidelines. (<a href="#section_2_2">2.2</a>)</li></ul>
</div>
<div></div>
<div></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>DOSAGE FORMS AND STRENGTHS</span></h1>
<div><ul>
<li>Delayed-Release Capsules: 4,000 USP units of lipase; 8,000 USP units of protease; 8,000 USP units of amylase (<a href="#section_3">3</a>)</li>
<li>Delayed-Release Capsules: 13,800 USP units of lipase; 27,600 USP units of protease; 27,600 USP units of amylase (<a href="#section_3">3</a>)</li>
<li>Delayed-Release Capsules: 20,700 USP units of lipase; 41,400 USP units of protease; 41,400 USP units of amylase (<a href="#section_3">3</a>)</li>
<li>Delayed-Release Capsules: 23,000 USP units of lipase; 46,000 USP units of protease; 46,000 USP units of amylase (<a href="#section_3">3</a>)</li>
</ul></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>CONTRAINDICATIONS</span></h1>
<div><ul><li>None. (<a href="#section_4">4</a>)</li></ul></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>WARNINGS AND PRECAUTIONS</span></h1>
<div><ul>
<li><span class="product-label-link" type="condition" conceptid="40482055" conceptname="Fibrosing colonopathy">Fibrosing colonopathy</span> is associated with high-dose use of pancreatic enzyme replacement. Exercise caution when doses of ULTRESA exceed 2,500 lipase units/kg of body weight per meal (or greater than 10,000 lipase units/kg of body weight per day). (<a href="#section_5_1">5.1</a>)</li>
<li>To avoid irritation of oral mucosa, do not chew ULTRESA or retain in mouth. (<a href="#section_5_2">5.2</a>)</li>
<li>Exercise caution when prescribing ULTRESA to patients with <span class="product-label-link" type="condition" conceptid="440674" conceptname="Gout">gout</span>, <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">renal impairment</span>, or <span class="product-label-link" type="condition" conceptid="4147761" conceptname="Hyperuricemia">hyperuricemia</span>. (<a href="#section_5_3">5.3</a>)</li>
<li>There is theoretical risk of viral transmission with all pancreatic enzyme products including ULTRESA. (<a href="#section_5_4">5.4</a>)</li>
<li>Exercise caution when administering pancrelipase to a patient with a known <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">allergy</span> to proteins of porcine origin. (<a href="#section_5_5">5.5</a>)</li>
</ul></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>ADVERSE REACTIONS</span></h1>
<div>
<ul><li>The most common adverse reactions (â‰¥7% of patients treated with ULTRESA) are <span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">headache</span>, pharyngolaryngeal <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span>, and <span class="product-label-link" type="condition" conceptid="318556" conceptname="Epistaxis">epistaxis</span>. (<a href="#section_6_1">6.1</a>)</li></ul>
<p class="Highlighta"><span class="Bold">To report SUSPECTED ADVERSE REACTIONS, contact APTALIS Pharma US, Inc. / Forest Laboratories, LLC at 1-800-472-2634 or FDA at 1-800-FDA-1088 or <span class="Underline">www.fda.gov/medwatch</span>.</span> </p>
</div>
<div></div>
<div></div>
</div>
<div></div>
<div>
<div></div>
<div></div>
<div></div>
</div>
<div></div>
<div></div>
<div>
<div></div>
<div></div>
</div>
<div><div></div></div>
<div></div>
<div></div>
<div></div>
<div>
<div></div>
<div></div>
<div></div>
<div></div>
</div>
<div></div>
<div></div>
<p class="HighlightsSeeReference">See 17 for PATIENT COUNSELING INFORMATION and Medication Guide.</p>
<p class="HighlightsRevision">Revised: 9/2014</p>
</div></td></tr></table></div>
<div id="Index" class="Index"><table cellspacing="5" cellpadding="5" width="100%" style="table-layout:fixed"><tr><td align="left" valign="top"><div>
<h1 class="Colspan">FULL PRESCRIBING INFORMATION: CONTENTS<a href="#footnote-content" name="footnote-reference-content">*</a>
</h1>
<h1><a href="#section-1" class="toc">1 INDICATIONS AND USAGE</a></h1>
<h1><a href="#section-2" class="toc">2 DOSAGE AND ADMINISTRATION</a></h1>
<h2><a href="#section-2.1" class="toc">2.1 Administration</a></h2>
<h2><a href="#section-2.2" class="toc">2.2 Dosage</a></h2>
<h1><a href="#section-3" class="toc">3 DOSAGE FORMS AND STRENGTHS</a></h1>
<h1><a href="#section-4" class="toc">4 CONTRAINDICATIONS</a></h1>
<h1><a href="#section-5" class="toc">5 WARNINGS AND PRECAUTIONS</a></h1>
<h2><a href="#section-5.1" class="toc">5.1 <span class="product-label-link" type="condition" conceptid="40482055" conceptname="Fibrosing colonopathy">Fibrosing Colonopathy</span></a></h2>
<h2><a href="#section-5.2" class="toc">5.2 Potential for Irritation to Oral Mucosa</a></h2>
<h2><a href="#section-5.3" class="toc">5.3 Potential for Risk of <span class="product-label-link" type="condition" conceptid="4147761" conceptname="Hyperuricemia">Hyperuricemia</span></a></h2>
<h2><a href="#section-5.4" class="toc">5.4 Potential for Viral Exposure from the Product Source</a></h2>
<h2><a href="#section-5.5" class="toc">5.5 <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">Allergic Reactions</span></a></h2>
<h1><a href="#section-6" class="toc">6 ADVERSE REACTIONS</a></h1>
<h2><a href="#section-6.1" class="toc">6.1 Clinical Trials Experience</a></h2>
<h2><a href="#section-6.2" class="toc">6.2 Postmarketing Experience</a></h2>
<h1><a href="#section-7" class="toc">7 DRUG INTERACTIONS</a></h1>
<h1><a href="#section-8" class="toc">8 USE IN SPECIFIC POPULATIONS</a></h1>
<h2><a href="#section-8.1" class="toc">8.1 Pregnancy</a></h2>
<h2><a href="#section-8.2" class="toc">8.3 Nursing Mothers</a></h2>
<h2><a href="#section-8.3" class="toc">8.4 Pediatric Use</a></h2>
<h2><a href="#section-8.4" class="toc">8.5 Geriatric Use</a></h2>
<h1><a href="#section-9" class="toc">10 OVERDOSAGE</a></h1>
<h1><a href="#section-10" class="toc">11 DESCRIPTION</a></h1>
<h1><a href="#section-11" class="toc">12 CLINICAL PHARMACOLOGY</a></h1>
<h2><a href="#section-11.1" class="toc">12.1 Mechanism of Action</a></h2>
<h2><a href="#section-11.2" class="toc">12.3 Pharmacokinetics </a></h2>
<h1><a href="#section-12" class="toc">13 NONCLINICAL TOXICOLOGY</a></h1>
<h2><a href="#section-12.1" class="toc">13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility</a></h2>
<h1><a href="#section-13" class="toc">14 CLINICAL STUDIES</a></h1>
<h1><a href="#section-14" class="toc">15 REFERENCES</a></h1>
<h1><a href="#section-15" class="toc">16 HOW SUPPLIED/STORAGE AND HANDLING</a></h1>
<h1><a href="#section-16" class="toc">17 PATIENT COUNSELING INFORMATION </a></h1>
<h2><a href="#section-16.1" class="toc">17.1 Dosing and Administration </a></h2>
<h2><a href="#section-16.2" class="toc">17.2 <span class="product-label-link" type="condition" conceptid="40482055" conceptname="Fibrosing colonopathy">Fibrosing Colonopathy</span></a></h2>
<h2><a href="#section-16.3" class="toc">17.3 <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">Allergic Reactions</span></a></h2>
<h2><a href="#section-16.4" class="toc">17.4 Pregnancy and Breast Feeding</a></h2>
<dl class="Footnote">
<dt><a href="#footnote-reference-content" name="footnote-content">*</a></dt>
<dd>Sections or subsections omitted from the full prescribing information are not listed.</dd>
</dl>
</div></td></tr></table></div>
<div class="Contents">
<h1>FULL PRESCRIBING INFORMATION</h1>
<div class="Section" data-sectionCode="48780-1">
<a name="section-1"></a><p></p>
</div>
<div class="Section" data-sectionCode="34067-9">
<a name="section_1"></a><a name="section-1"></a><p></p>
<h1>1 INDICATIONS AND USAGE</h1>
<p class="First">ULTRESA (pancrelipase) is indicated for the treatment of exocrine <span class="product-label-link" type="condition" conceptid="4243784" conceptname="Pancreatic insufficiency">pancreatic insufficiency</span> due to <span class="product-label-link" type="condition" conceptid="441267" conceptname="Cystic fibrosis">cystic fibrosis</span> or other conditions.</p>
</div>
<div class="Section" data-sectionCode="34068-7">
<a name="section_2"></a><a name="section-2"></a><p></p>
<h1>2 DOSAGE AND ADMINISTRATION</h1>
<p class="First">ULTRESA is not interchangeable with other pancrelipase products.</p>
<p>ULTRESA is orally administered.  Therapy should be initiated at the lowest recommended dose and gradually increased.  The dosage of ULTRESA should be individualized based on clinical symptoms, the degree of <span class="product-label-link" type="condition" conceptid="200146" conceptname="Pancreatic steatorrhea">steatorrhea</span> present, and the fat content of the diet as described in the Limitations on Dosing below [see <span class="Italics">Dosage and Administration (<a href="#section_2_2">2.2</a>) and Warnings and Precautions (<a href="#section_5_1">5.1</a>)</span>].
</p>
<div class="Section" data-sectionCode="42229-5">
<a name="section_2_1"></a><a name="section-2.1"></a><p></p>
<h2>2.1 Administration</h2>
<p class="First"><span class="Underline"><span class="Italics">Infants (up to 12 months)</span></span></p>
<p>ULTRESA should be administered to infants immediately prior to each feeding, using a dosage of 4,000 lipase units (one capsule) per 120 mL of formula or per breast-feeding. Contents of the capsule may be administered with a small amount of applesauce, or other acidic food with a pH of 4.5 or less (e.g., commercially available preparations of bananas, or pears). Contents of the capsule may also be administered directly to the mouth and immediately give formula or breast milk to ensure complete ingestion.</p>
<p>Administration should be followed by breast milk or formula. Contents of the capsule <span class="Bold">should not</span> be mixed directly into formula or breast milk as this may diminish efficacy. Care should be taken to ensure that ULTRESA is not crushed or chewed or retained in the mouth, to avoid irritation of the oral mucosa.</p>
<p></p>
<p><span class="Underline"><span class="Italics">Children and Adults</span></span></p>
<p>ULTRESA should be taken during meals or snacks, with sufficient fluid. ULTRESA capsules should be swallowed whole. <span class="Bold">ULTRESA capsules and capsule contents should not be crushed or chewed.</span></p>
<p>For patients who are unable to swallow intact capsules, the capsules may be carefully opened and the contents sprinkled on a small amount ofÂ soft acidic food with pH of 4.5 or less such as applesauce orÂ yogurt at room temperature.</p>
<p>The ULTRESA-soft food mixture should be swallowed immediately without crushing or chewing, and followed with water or juice to ensure complete ingestion. Care should be taken to ensure that no drug is retained in the mouth to avoid mucosal irritation.</p>
<p>Any unused portion of capsule contents should be discarded, and not used for subsequent dosing. The remaining exposed contents may lose potency and become less effective.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section_2_2"></a><a name="section-2.2"></a><p></p>
<h2>2.2 Dosage</h2>
<p class="First">Dosage recommendations for pancreatic enzyme replacement therapy were published following the <span class="product-label-link" type="condition" conceptid="441267" conceptname="Cystic fibrosis">Cystic Fibrosis</span> Foundation Consensus Conferences.<span class="Sup">1,2,3</span> ULTRESA should be administered in a manner consistent with the recommendations of the Conferences provided in the following paragraphs, with one exception. The Conferences recommend doses of 2,000 to 4,000 lipase units in infants up to 12 months. ULTRESA is available in a 4,000 lipase unit capsule. The recommended dose of ULTRESA in infants up to 12 months is 4,000 lipase units.Â Patients may be dosed on a fat ingestion-based or actual body weight-based dosing scheme.</p>
<p><span class="Underline"><span class="Italics">Infants (up to 12 months)</span></span></p>
<p>Infants may be given 4,000 lipase units (one capsule) per 120 mL of formula or per breast-feeding. Do not mix ULTRESA capsule contents directly into formula or breast milk prior to administration [<span class="Italics">see Dosage and Administration (<a href="#section_2_1">2.1</a>)</span>].</p>
<p><span class="Underline"><span class="Italics">Children Older than 12 Months and Younger than 4 Years</span></span></p>
<p>Enzyme dosing should begin with 1,000 lipase units/kg of body weight per meal for children less than age 4 years to a maximum of 2,500 lipase units/kg of body weight per meal (or less than or equal to 10,000 lipase units/kg of body weight per day), or less than 4,000 lipase units/g fat ingested per day.</p>
<p><span class="Underline"><span class="Italics">Children 4 Years and Older and Adults</span></span></p>
<p>Enzyme dosing should begin with 500 lipase units/kg of body weight per meal for those older than age 4 years to a maximum of 2,500 lipase units/kg of body weight per meal (or less than or equal to 10,000 lipase units/kg of body weight per day), or less than 4,000 lipase units/g fat ingested per day.</p>
<p>Usually, half of the prescribed ULTRESA dose for an individualized full meal should be given with each snack. The total daily dosage should reflect approximately three meals plus two or three snacks per day.</p>
<p>Enzyme doses expressed as lipase units/kg of body weight per meal should be decreased in older patients because they weigh more but tend to ingest less fat per kilogram of body weight.</p>
<p><span class="Underline"><span class="Italics">Limitations on Dosing:</span></span></p>
<p>Dosing should not exceed the recommended maximum dosage set forth by the <span class="product-label-link" type="condition" conceptid="441267" conceptname="Cystic fibrosis">Cystic Fibrosis</span> Foundation Consensus Conferences Guidelines.<span class="Sup">1,2,3 </span>If symptoms and signs of <span class="product-label-link" type="condition" conceptid="200146" conceptname="Pancreatic steatorrhea">steatorrhea</span> persist, the dosage may be increased by a healthcare professional. Patients should be instructed not to increase the dosage on their own. There is great inter-individual variation in response to enzymes; thus, a range of doses is recommended. Changes in dosage may require an adjustment period of several days. If doses are to exceed 2,500 lipase units/kg of body weight per meal, further investigation is warranted. Doses greater than 2,500 lipase units/kg of body weight per meal (or greater than 10,000 lipase units/kg of body weight per day) should be used with caution and only if they are documented to be effective by 3-day fecal fat measures that indicate a significantly improved coefficient of fat absorption. Doses greater than 6,000 lipase units/kg of body weight per meal have been associated with <span class="product-label-link" type="condition" conceptid="4078069" conceptname="Stenosis of colon">colonic stricture</span>, indicative of <span class="product-label-link" type="condition" conceptid="40482055" conceptname="Fibrosing colonopathy">fibrosing colonopathy</span>, in children less than 12 years of age [see <span class="Italics">Warnings and Precautions (<a href="#section_5_1">5.1</a>)</span>]. Patients currently receiving higher doses than 6,000 lipase units/kg of body weight per meal should be examined and the dosage either immediately decreased or titrated downward to a lower range.</p>
</div>
</div>
<div class="Section" data-sectionCode="43678-2">
<a name="section_3"></a><a name="section-3"></a><p></p>
<h1>3 DOSAGE FORMS AND STRENGTHS</h1>
<p class="First">The active ingredient in ULTRESA evaluated in clinical trials is lipase. ULTRESA is dosed by lipase units. Other active ingredients include protease and amylase.</p>
<p>ULTRESA is available inÂ 4 color coded delayed-release capsule strengths. Each ULTRESA delayed-release capsule strength contains the specified amounts of lipase, protease, and amylase as follows:</p>
<ul>
<li>4,000 USP units of lipase; 8,000 USP units of protease; 8,000 USP units of amylase delayed-release capsules have a flesh opaque cap printed with â€œULTRESAâ€? and blue opaque body printed with â€œ4000â€? in black.</li>
<li>13,800 USP units of lipase; 27,600 USP units of protease; 27,600 USP units of amylase delayed-release capsules have a white cap printed with â€œ13800ULâ€? and yellow body printed with â€œAXCAâ€? in black.</li>
<li>20,700 USP units of lipase; 41,400 USP units of protease; 41,400 USP units of amylase delayed-release capsules have a gray cap printed with â€œ20700ULâ€? and white body printed with â€œAXCAâ€? in black.</li>
<li>23,000 USP units of lipase; 46,000 USP units of protease; 46,000 USP units of amylase delayed-release capsules have a light gray cap printed with â€œ23000ULâ€? and yellow body printed with â€œAXCAâ€? in black.</li>
</ul>
</div>
<div class="Section" data-sectionCode="34070-3">
<a name="section_4"></a><a name="section-4"></a><p></p>
<h1>4 CONTRAINDICATIONS</h1>
<p class="First">None.</p>
</div>
<div class="Section" data-sectionCode="43685-7">
<a name="section_5"></a><a name="section-5"></a><p></p>
<h1>5 WARNINGS AND PRECAUTIONS</h1>
<div class="Section" data-sectionCode="42229-5">
<a name="section_5_1"></a><a name="section-5.1"></a><p></p>
<h2>5.1 <span class="product-label-link" type="condition" conceptid="40482055" conceptname="Fibrosing colonopathy">Fibrosing Colonopathy</span></h2>
<p class="First"><span class="product-label-link" type="condition" conceptid="40482055" conceptname="Fibrosing colonopathy">Fibrosing colonopathy</span> has been reported following treatment with different pancreatic enzyme products.<span class="Sup">4, 5</span> <span class="product-label-link" type="condition" conceptid="40482055" conceptname="Fibrosing colonopathy">Fibrosing colonopathy</span> is a rare, serious adverse reaction initially described in association with high-dose pancreatic enzyme use, usually with use over a prolonged period of time and most commonly reported in pediatric patients with <span class="product-label-link" type="condition" conceptid="441267" conceptname="Cystic fibrosis">cystic fibrosis</span>. The underlying mechanism of <span class="product-label-link" type="condition" conceptid="40482055" conceptname="Fibrosing colonopathy">fibrosing colonopathy</span> remains unknown. Doses of pancreatic enzyme products exceeding 6,000 lipase units/kg of body weight per meal have been associated with <span class="product-label-link" type="condition" conceptid="4078069" conceptname="Stenosis of colon">colonic stricture</span> in children less than 12 years of age.<span class="Sup">1</span> Patients with <span class="product-label-link" type="condition" conceptid="40482055" conceptname="Fibrosing colonopathy">fibrosing colonopathy</span> should be closely monitored because some patients may be at risk of progressing to stricture formation. It is uncertain whether regression of <span class="product-label-link" type="condition" conceptid="40482055" conceptname="Fibrosing colonopathy">fibrosing colonopathy</span> occurs. It is generally recommended, unless clinically indicated, that enzyme doses should be less than 2,500 lipase units/kg of body weight per meal (or less than 10,000 lipase units/kg of body weight per day) or less than 4,000 lipase units/g fat ingested per day [see<span class="Italics"> Dosage and Administration (<a href="#section_2_2">2.2</a>)</span>].
								</p>
<p>Doses greater than 2,500 lipase units/kg of body weight per meal (or greater than 10,000 lipase units/kg of body weight per day) should be used with caution and only if they are documented to be effective by 3-day fecal fat measures that indicate a significantly improved coefficient of fat absorption. Patients receiving higher doses than 6,000 lipase units/kg of body weight per meal should be examined and the dosage either immediately decreased or titrated downward to a lower range.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section_5_2"></a><a name="section-5.2"></a><p></p>
<h2>5.2 Potential for Irritation to Oral Mucosa</h2>
<p class="First">Care should be taken to ensure that no drug is retained in the mouth. ULTRESA should not be crushed or chewed or mixed in foods having a pH greater than 4.5. These actions can disrupt the protective enteric coating resulting in early release of enzymes, irritation of oral mucosa, and/or loss of enzyme activity [see<span class="Italics"> Dosage and Administration (<a href="#section_2_1">2.1</a>) and Patient Counseling Information (<a href="#section_17_1">17.1</a>)</span>] For patients who are unable to swallow intact capsules, the contents may be sprinkled onÂ soft acidic food with pH 4.5 or less such as applesauce orÂ yogurt. The ULTRESA-soft food mixture should be swallowed immediately and followed with water or juice to ensure complete ingestion.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section_5_3"></a><a name="section-5.3"></a><p></p>
<h2>5.3 Potential for Risk of <span class="product-label-link" type="condition" conceptid="4147761" conceptname="Hyperuricemia">Hyperuricemia</span></h2>
<p class="First">Caution should be exercised when prescribing ULTRESA to patients with <span class="product-label-link" type="condition" conceptid="440674" conceptname="Gout">gout</span>, <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">renal impairment</span>, or <span class="product-label-link" type="condition" conceptid="4147761" conceptname="Hyperuricemia">hyperuricemia</span>. Porcine-derived pancreatic enzyme products contain purines that may increase blood uric acid levels.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section_5_4"></a><a name="section-5.4"></a><p></p>
<h2>5.4 Potential for Viral Exposure from the Product Source</h2>
<p class="First">ULTRESA is sourced from pancreatic tissue fromÂ swine used for food consumption. Although the risk that ULTRESA will transmit an infectious agent to humans has been reduced by testing for certain viruses during manufacturing and by inactivating certain viruses during manufacturing, there is a theoretical risk for transmission of viral disease, including diseases caused by novel or unidentified viruses. Thus, the presence of porcine viruses that might infect humans cannot be definitely excluded. However, no cases of transmission of an infectious illness associated with the use of porcine pancreatic extracts have been reported.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section_5_5"></a><a name="section-5.5"></a><p></p>
<h2>5.5 <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">Allergic Reactions</span></h2>
<p class="First">Caution should be exercised when administering pancrelipase to a patient with a known <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">allergy</span> to proteins of porcine origin. Rarely, severe <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">allergic reactions</span> including <span class="product-label-link" type="condition" conceptid="441202" conceptname="Anaphylaxis">anaphylaxis</span>, <span class="product-label-link" type="condition" conceptid="317009" conceptname="Asthma">asthma</span>, <span class="product-label-link" type="condition" conceptid="139900" conceptname="Urticaria">hives</span>, and <span class="product-label-link" type="condition" conceptid="4169287" conceptname="Itching of skin">pruritus</span>, have been reported with other pancreatic enzyme products with different formulations of the same active ingredient (pancrelipase). The risks and benefits of continued ULTRESA treatment in patients with severe <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">allergy</span> should be taken into consideration with the overall clinical needs of the patient.</p>
</div>
</div>
<div class="Section" data-sectionCode="34084-4">
<a name="section_6"></a><a name="section-6"></a><p></p>
<h1>6 ADVERSE REACTIONS</h1>
<p class="First">The most serious adverse reactions reported with different pancreatic enzyme products of the same active ingredient (pancrelipase) that are described elsewhere in the label include <span class="product-label-link" type="condition" conceptid="40482055" conceptname="Fibrosing colonopathy">fibrosing colonopathy</span>, <span class="product-label-link" type="condition" conceptid="4147761" conceptname="Hyperuricemia">hyperuricemia</span> and <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">allergic reactions</span> [see <span class="Italics">Warnings and Precautions (<a href="#section_5_1">5.1</a>, <a href="#section_5_3">5.3</a> and <a href="#section_5_5">5.5</a>)</span>].
						</p>
<div class="Section" data-sectionCode="42229-5">
<a name="section_6_1"></a><a name="section-6.1"></a><p></p>
<h2>6.1 Clinical Trials Experience</h2>
<p class="First">Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in clinical practice.</p>
<p>The short-term safety of ULTRESA was assessed in two clinical trials conducted in 40 patients with exocrine <span class="product-label-link" type="condition" conceptid="4243784" conceptname="Pancreatic insufficiency">pancreatic insufficiency</span> (EPI) due to <span class="product-label-link" type="condition" conceptid="441267" conceptname="Cystic fibrosis">cystic fibrosis</span> (CF). Study 1 was conducted in 31 patients, ages 8 years to 37 years; Study 2 was conducted in 9 patients, ages 7 years to 11 years.</p>
<p>Study 1 was a randomized, double-blind, placebo-controlled, crossover study of 31 patients, ages 8 to 37 years, with EPI due to CF.  In this study, patients were randomized to receive ULTRESA at doses not to exceed 2,500 lipase units per kilogram per meal or matching placebo for 6 to 7 days of treatment, followed by crossover to the alternate treatment for an additional 6 to 7 days.  The mean daily dose of ULTRESA was 6,270 lipase units per kilogram body weight per day.  The mean exposure to ULTRESA during this study was 5.4 days.</p>
<p>The most common adverse reactions (â‰¥7%) were <span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">headache</span>, pharyngolaryngeal <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span>, and <span class="product-label-link" type="condition" conceptid="318556" conceptname="Epistaxis">epistaxis</span>.  Table 1 enumerates adverse reactions that occurred in at least 2 patients (greater than or equal to 7%) treated with ULTRESA at a higher rate than with placebo in Study 1. </p>
<a name="table1"></a><table frame="box" width="100%">
<caption><span></span></caption>
<colgroup>
<col align="left">
<col align="center">
<col align="center">
</colgroup>
<tbody class="Headless">
<tr class="First"><td align="center" colspan="3">
<span class="Bold">TABLE 1</span><br><span class="Bold">Adverse Reactions Occurring in at Least 2 Patients (â‰¥ 7%) in <span class="product-label-link" type="condition" conceptid="441267" conceptname="Cystic fibrosis">Cystic Fibrosis</span> (Study 1)</span>
</td></tr>
<tr>
<td align="left"><span class="Bold">Adverse Reaction</span></td>
<td align="center">
<span class="Bold">ULTRESA</span><br><span class="Bold">n=30</span><br><span class="Bold">n (%)</span>
</td>
<td align="center">
<span class="Bold">Placebo </span><br><span class="Bold">n=31 </span><br><span class="Bold">n (%)</span>
</td>
</tr>
<tr>
<td align="left"><span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">Headache</span></td>
<td align="center">2 (7%)</td>
<td align="center">1 (3%)</td>
</tr>
<tr>
<td align="left">Pharyngolaryngeal <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">Pain</span></td>
<td align="center">2 (7%)</td>
<td align="center">1 (3%)</td>
</tr>
<tr class="Last">
<td align="left"><span class="product-label-link" type="condition" conceptid="318556" conceptname="Epistaxis">Epistaxis</span></td>
<td align="center">2 (7%)</td>
<td align="center">0</td>
</tr>
</tbody>
</table>
<p>Study 2 was an open-label study of 9 patients, ages 7 years to 11 years, with EPI due to CF.  After a screening period of up to 15 days on individually-titrated doses of ULTRESA not to exceed 2,500 lipase units per kilogram per meal, patients entered a washout phase (no treatment) of up to 7 days before returning to a treatment phase of up to 12 days on the same individually-titrated dose of ULTRESA.  Two patients discontinued during the washout phase leaving 7 patients in the treatment phase.  The mean daily dose of ULTRESA was 6,361 lipase units per kilogram body weight per day during the last 4 days of the screening phase, and was 6,846 lipase units per kilogram body weight per day during the treatment phase.  The mean duration of the treatment phase was 5.7 days.</p>
<p>Adverse reactions that occurred during treatment with ULTRESA were <span class="product-label-link" type="condition" conceptid="4195085" conceptname="Nasal congestion">nasal congestion</span> (14%), <span class="product-label-link" type="condition" conceptid="24134" conceptname="Neck pain">neck pain</span> (14%), beta-hemolytic <span class="product-label-link" type="condition" conceptid="437779" conceptname="Streptococcal infectious disease">streptococcal infection</span> (11%), <span class="product-label-link" type="condition" conceptid="380733" conceptname="Otalgia">ear pain</span> (11%), and <span class="product-label-link" type="condition" conceptid="315085" conceptname="Lymphadenopathy">lymphadenopathy</span> (11%).</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section_6_2"></a><a name="section-6.2"></a><p></p>
<h2>6.2 Postmarketing Experience</h2>
<p class="First">Postmarketing data for ULTRESA has been available since 2003.  The safety data is similar to that described below.  Because these reactions are reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency or establish a causal relationship to drug exposure.</p>
<p>Pancreatic enzyme products (delayed and immediate-release) with different formulations of the same active ingredient (pancrelipase) have been used for the treatment of patients with exocrine <span class="product-label-link" type="condition" conceptid="4243784" conceptname="Pancreatic insufficiency">pancreatic insufficiency</span> due to <span class="product-label-link" type="condition" conceptid="441267" conceptname="Cystic fibrosis">cystic fibrosis</span> and other conditions, such as <span class="product-label-link" type="condition" conceptid="195596" conceptname="Chronic pancreatitis">chronic pancreatitis</span>. The long-term safety profile of these products has been described in the medical literature. The most serious adverse events included <span class="product-label-link" type="condition" conceptid="40482055" conceptname="Fibrosing colonopathy">fibrosing colonopathy</span>, <span class="product-label-link" type="condition" conceptid="4052560" conceptname="Distal intestinal obstruction syndrome">distal intestinal obstruction syndrome</span> (<span class="product-label-link" type="condition" conceptid="4052560" conceptname="Distal intestinal obstruction syndrome">DIOS</span>), recurrence of pre-existing carcinoma, and severe <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">allergic reactions</span> including <span class="product-label-link" type="condition" conceptid="441202" conceptname="Anaphylaxis">anaphylaxis</span>, <span class="product-label-link" type="condition" conceptid="317009" conceptname="Asthma">asthma</span>, <span class="product-label-link" type="condition" conceptid="139900" conceptname="Urticaria">hives</span>, and <span class="product-label-link" type="condition" conceptid="4169287" conceptname="Itching of skin">pruritus</span>. The most commonly reported adverse events were <span class="product-label-link" type="condition" conceptid="4302537" conceptname="Digestive system finding">gastrointestinal disorders</span>, including <span class="product-label-link" type="condition" conceptid="200219" conceptname="Abdominal pain">abdominal pain</span>, <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span>, <span class="product-label-link" type="condition" conceptid="4012503" conceptname="Excessive upper gastrointestinal gas">flatulence</span>, <span class="product-label-link" type="condition" conceptid="75860" conceptname="Constipation">constipation</span> and <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span>, and <span class="product-label-link" type="condition" conceptid="140842" conceptname="Changes in skin texture">skin disorders</span> including <span class="product-label-link" type="condition" conceptid="4169287" conceptname="Itching of skin">pruritus</span>, <span class="product-label-link" type="condition" conceptid="139900" conceptname="Urticaria">urticaria</span> and <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">rash</span>. </p>
</div>
</div>
<div class="Section" data-sectionCode="34073-7">
<a name="section_7"></a><a name="section-7"></a><p></p>
<h1>7 DRUG INTERACTIONS</h1>
<p class="First">No drug interactions have been identified. No formal interaction studies have been conducted.</p>
</div>
<div class="Section" data-sectionCode="43684-0">
<a name="section_8"></a><a name="section-8"></a><p></p>
<h1>8 USE IN SPECIFIC POPULATIONS</h1>
<div class="Section" data-sectionCode="42228-7">
<a name="section_8_1"></a><a name="section-8.1"></a><p></p>
<h2>8.1 Pregnancy</h2>
<p class="First"><span class="Underline">Teratogenic effects</span></p>
<p>Pregnancy Category C.  Animal reproduction studies have not been conducted with pancrelipase.  It is also not known whether pancrelipase can cause fetal harm when administered to a pregnant woman or can affect reproduction capacity.  ULTRESA should be given to a pregnant woman only if clearly needed. The risk and benefit of pancrelipase should be considered in the context of the need to provide adequate nutritional support to a pregnant woman with exocrine <span class="product-label-link" type="condition" conceptid="4243784" conceptname="Pancreatic insufficiency">pancreatic insufficiency</span>.  Adequate caloric intake during pregnancy is important for normal maternal <span class="product-label-link" type="condition" conceptid="4134784" conceptname="Weight increased">weight gain</span> and fetal growth.  Reduced maternal <span class="product-label-link" type="condition" conceptid="4134784" conceptname="Weight increased">weight gain</span> and <span class="product-label-link" type="condition" conceptid="4090739" conceptname="Nutritional disorder">malnutrition</span> can be associated with adverse pregnancy outcomes.</p>
</div>
<div class="Section" data-sectionCode="34080-2">
<a name="section_8_3"></a><a name="section-8.2"></a><p></p>
<h2>8.3 Nursing Mothers</h2>
<p class="First">It is not known whether this drug is excreted in human milk.  Because many drugs are excreted in human milk, caution should be exercised when ULTRESA is administered to a nursing woman.  The risk and benefit of pancrelipase should be considered in the context of the need to provide adequate nutritional support to a nursing mother with exocrine <span class="product-label-link" type="condition" conceptid="4243784" conceptname="Pancreatic insufficiency">pancreatic insufficiency</span>.</p>
</div>
<div class="Section" data-sectionCode="34081-0">
<a name="section_8_4"></a><a name="section-8.3"></a><p></p>
<h2>8.4 Pediatric Use</h2>
<p class="First">The short-term safety and efficacy of ULTRESA were assessed in two clinical studies in pediatric patients with exocrine <span class="product-label-link" type="condition" conceptid="4243784" conceptname="Pancreatic insufficiency">pancreatic insufficiency</span> due to <span class="product-label-link" type="condition" conceptid="441267" conceptname="Cystic fibrosis">cystic fibrosis</span>; one study included patients aged 8 years to 17 years, and the other included patients aged 7 years to 11 years.</p>
<p>Study 1 was a randomized, double-blind, placebo-controlled crossover study of 31 patients with exocrine <span class="product-label-link" type="condition" conceptid="4243784" conceptname="Pancreatic insufficiency">pancreatic insufficiency</span> due to <span class="product-label-link" type="condition" conceptid="441267" conceptname="Cystic fibrosis">cystic fibrosis</span> including 2 children aged 8 to 11 years, and 12 adolescents aged 12 to 17 years. The safety and efficacy in pediatric patients in this study were similar to that in adult patients [see <span class="Italics">Adverse Reactions (<a href="#section_6_1">6.1</a>) and Clinical Studies (<a href="#section_14">14</a>)</span>].</p>
<p>Study 2 was an open-label study of 9 pediatric patients, ages 7 years to 11 years, with exocrine <span class="product-label-link" type="condition" conceptid="4243784" conceptname="Pancreatic insufficiency">pancreatic insufficiency</span> due to <span class="product-label-link" type="condition" conceptid="441267" conceptname="Cystic fibrosis">cystic fibrosis</span>. Patients showed similar control of fat <span class="product-label-link" type="condition" conceptid="194993" conceptname="Intestinal malabsorption">malabsorption</span> as in the treatment arm of Study 1 [see <span class="Italics">Adverse Reactions (<a href="#section_6_1">6.1</a>) and Clinical Studies (<a href="#section_14">14</a>)</span>].</p>
<p>The safety and efficacy of pancreatic enzyme products with different formulations of pancrelipase consisting of the same active ingredient (lipases, proteases, and amylases) for treatment of children with exocrine <span class="product-label-link" type="condition" conceptid="4243784" conceptname="Pancreatic insufficiency">pancreatic insufficiency</span> due to <span class="product-label-link" type="condition" conceptid="441267" conceptname="Cystic fibrosis">cystic fibrosis</span> have been described in the medical literature and through clinical experience.</p>
<p>Dosing of pediatric patients should be in accordance with recommended guidance from the <span class="product-label-link" type="condition" conceptid="441267" conceptname="Cystic fibrosis">Cystic Fibrosis</span> Foundation Consensus Conferences. Doses of other pancreatic enzyme products exceeding 6,000 lipase units/kg of body weight per meal have been associated with <span class="product-label-link" type="condition" conceptid="40482055" conceptname="Fibrosing colonopathy">fibrosing colonopathy</span> and <span class="product-label-link" type="condition" conceptid="4078069" conceptname="Stenosis of colon">colonic strictures</span> in children less than 12 years of age [see<span class="Italics"> Warnings and Precautions (<a href="#section_5_1">5.1</a>)]</span>.</p>
</div>
<div class="Section" data-sectionCode="34082-8">
<a name="section-8.4"></a><p></p>
<h2>8.5 Geriatric Use</h2>
<p class="First">Clinical studies of ULTRESA did not include sufficient numbers of subjects aged 65 and over to determine whether they respond differently from younger subjects.  Other reported clinical experience has not identified differences in responses between the elderly and younger patients. In general, dose selection for an elderly patient should be cautious, usually starting at the low end of the dosing range, reflecting the greater frequency of decreased hepatic, renal, or cardiac function, and of concomitant disease or other drug therapy.</p>
</div>
</div>
<div class="Section" data-sectionCode="34088-5">
<a name="section_10"></a><a name="section-9"></a><p></p>
<h1>10 OVERDOSAGE</h1>
<p class="First"> There have been no reports of <span class="product-label-link" type="condition" conceptid="4208104" conceptname="Drug overdose">overdose</span> in clinical trials or postmarketing surveillance with ULTRESA.  Chronic high doses of pancreatic enzyme products have been associated with <span class="product-label-link" type="condition" conceptid="40482055" conceptname="Fibrosing colonopathy">fibrosing colonopathy</span> and <span class="product-label-link" type="condition" conceptid="4078069" conceptname="Stenosis of colon">colonic strictures</span> [see <span class="Italics">Dosage and Administration (<a href="#section_2">2</a>) and Warnings and Precautions (<a href="#section_5_1">5.1</a>)</span>].  High doses of pancreatic enzyme products have been associated with <span class="product-label-link" type="condition" conceptid="4057743" conceptname="Hyperuricuria">hyperuricosuria</span> and <span class="product-label-link" type="condition" conceptid="4147761" conceptname="Hyperuricemia">hyperuricemia</span>, and should be used with caution in patients with a history of <span class="product-label-link" type="condition" conceptid="4147761" conceptname="Hyperuricemia">hyperuricemia</span>, <span class="product-label-link" type="condition" conceptid="440674" conceptname="Gout">gout</span>, or <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">renal impairment</span> [see<span class="Italics"> Warnings and Precautions (<a href="#section_5_3">5.3</a>)</span>].</p>
</div>
<div class="Section" data-sectionCode="34089-3">
<a name="section_11"></a><a name="section-10"></a><p></p>
<h1>11 DESCRIPTION</h1>
<p class="First">ULTRESA is a pancreatic enzyme preparation consisting of pancrelipase, an extract derived from porcine pancreatic glands. Pancrelipase contains multiple enzyme classes, including porcine-derived lipases, amylases, and proteases.</p>
<p>Pancrelipase is a beige-white amorphous powder. It is miscible in water and practically insoluble or insoluble in alcohol and ether.</p>
<p>Each delayed-release capsule for oral administration contains enteric-coatedÂ beads (1.7 mm in diameter and 1.9 mm thick for 4,000 USP lipase units,Â approximately 2.0 mm in diameter and 2.0 â€“ 2.4 mm thick for 13,800, 20,700, and 23,000 USP lipase units).</p>
<p>The active ingredient evaluated in clinical trials is lipase. ULTRESA is dosed by lipase units. Other active ingredients include protease and amylase.</p>
<p>ULTRESA contains the following inactive ingredients: colloidal silicon dioxide, croscarmellose sodium, hydrogenated castor oil, hypromellose phthalate, magnesium stearate, microcrystalline cellulose, talc, and triethyl citrate.</p>
<p><span class="Underline">4,000 USP units of lipase</span>; 8,000 USP units of protease; 8,000 USP units of amylase. The hypromellose delayed-release capsules have a flesh opaque cap and blue opaque body, printed with â€œULTRESAâ€? on the cap and â€œ4000â€? on the body in black ink. The capsule shell contains hypromellose, titanium dioxide, FD&amp;C Blue 1, red iron oxide, and capsule imprint ink.</p>
<p><span class="Underline">13,800 USP units of lipase</span>; 27,600 USP units of protease; 27,600 USP units of amylase. The hard gelatin delayed-release capsules have a white cap and yellow body printed with â€œ13800ULâ€? on cap and â€œAXCAâ€? on the body in black ink. The capsule shell contains gelatin, titanium dioxide, yellow iron oxide, and capsule imprint ink.</p>
<p><span class="Underline">20,700 USP units of lipase</span>; 41,400 USP units of protease; 41,400 USP units of amylase. The hard gelatin delayed-release capsules have a gray cap and white body printed with â€œ20700ULâ€? on cap and â€œAXCAâ€? on the body in black ink. The capsule shell contains gelatin, titanium dioxide, black iron oxide, and capsule imprint ink.</p>
<p><span class="Underline">23,000 USP units of lipase</span>; 46,000 USP units of protease; 46,000 USP units of amylase. The hard gelatin delayed-release capsules have a light gray cap and yellow body printed with â€œ23000ULâ€? on cap and â€œAXCAâ€? on the body in black ink. The capsule shell contains gelatin, titanium dioxide, yellow iron oxide, black iron oxide, and capsule imprint ink.</p>
<p>The black radial imprinting on the capsule contains iron oxide black as colorant, shellac, and propylene glycol. It may also contain strong <span class="product-label-link" type="condition" conceptid="4184927" conceptname="Ammonia">ammonia</span> solution, and potassium hydroxide.</p>
</div>
<div class="Section" data-sectionCode="34090-1">
<a name="section_12"></a><a name="section-11"></a><p></p>
<h1>12 CLINICAL PHARMACOLOGY</h1>
<div class="Section" data-sectionCode="43679-0">
<a name="section_12_1"></a><a name="section-11.1"></a><p></p>
<h2>12.1 Mechanism of Action</h2>
<p class="First">The pancreatic enzymes in ULTRESA catalyze the hydrolysis of fats to monoglycerides, glycerol and free fatty acids, proteins into peptides and amino acids, and starches into dextrins and short chain sugars such as maltose and maltotriose in the duodenum and proximal small intestine, thereby acting like digestive enzymes physiologically secreted by the pancreas.</p>
</div>
<div class="Section" data-sectionCode="43682-4">
<a name="section_12_3"></a><a name="section-11.2"></a><p></p>
<h2>12.3 Pharmacokinetics </h2>
<p class="First">The pancreatic enzymes in ULTRESA are enteric-coated to minimize destruction or inactivation in gastric acid. ULTRESA is designed to release most of the enzymes <span class="Italics">in vivo</span> at pH greater than 5.5. Pancreatic enzymes are not absorbed from the gastrointestinal tract in appreciable amounts.</p>
</div>
</div>
<div class="Section" data-sectionCode="43680-8">
<a name="section_13"></a><a name="section-12"></a><p></p>
<h1>13 NONCLINICAL TOXICOLOGY</h1>
<div class="Section" data-sectionCode="34083-6">
<a name="section_13_1"></a><a name="section-12.1"></a><p></p>
<h2>13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility</h2>
<p class="First">Carcinogenicity, genetic toxicology, and animal fertility studies have not been performed with pancrelipase.</p>
</div>
</div>
<div class="Section" data-sectionCode="34092-7">
<a name="section_14"></a><a name="section-13"></a><p></p>
<h1>14 CLINICAL STUDIES</h1>
<p class="First">The short-term efficacy and safety of ULTRESA were evaluated in 2 studies conducted in 40 patients, ages 7 to 37 years, with exocrine <span class="product-label-link" type="condition" conceptid="4243784" conceptname="Pancreatic insufficiency">pancreatic insufficiency</span> associated with <span class="product-label-link" type="condition" conceptid="441267" conceptname="Cystic fibrosis">cystic fibrosis</span>.</p>
<p>Study 1 was a randomized, double-blind, placebo-controlled, crossover study of 31 patients, ages 8 to 37 years, with exocrine <span class="product-label-link" type="condition" conceptid="4243784" conceptname="Pancreatic insufficiency">pancreatic insufficiency</span> due to <span class="product-label-link" type="condition" conceptid="441267" conceptname="Cystic fibrosis">cystic fibrosis</span>.   The final analysis population was limited to 24 patients, who completed both treatment periods and had stool results available for each treatment period.  Patients were randomized to receive ULTRESA (at a dose not to exceed 2,500 lipase units per kilogram per meal or snack) or matching placebo for 6 to 7 days of treatment followed by crossover to the alternate treatment for an additional 6 to 7 days.  The mean dose during the controlled treatment periods was 6,270 lipase units per kilogram per day.  All patients consumed a high-fat diet (2 grams of fat per kilogram of body weight per day) during the treatment periods.</p>
<p>The coefficient of fat absorption (CFA) was determined by a 72-hour stool collection during both treatments, when both fat excretion and fat ingestion were measured.  Each patientâ€™s CFA during placebo treatment was used as their no-treatment CFA value.</p>
<p>Mean CFA was 89% with ULTRESA treatment compared to 56% with placebo treatment. The mean difference in CFA was 35 percentage points in favor of ULTRESA treatment with 95% CI: (25, 45) and p&lt;0.0001.</p>
<p>Subgroup analyses of the CFA results showed that mean change in CFA was greater in patients with lower no-treatment (placebo) CFA values than in patients with higher no-treatment (placebo) CFA values. There were similar responses to ULTRESA by age and gender.</p>
<p>The coefficient of nitrogen absorption (CNA) was determined by a 72 hour stool collection during both treatments, when nitrogen excretion was measured and nitrogen ingestion from a controlled diet was estimated (based on the assumption that proteins contain 16% nitrogen).  Each patientâ€™s CNA during placebo treatment was used as their no treatment CNA value.</p>
<p>In Study 1, mean CNA was 84% with ULTRESA treatment compared to 59% with placebo treatment. The mean difference in CNA was 26 percentage points in favor of ULTRESA treatment with 95% CI: (18, 33) and p&lt;0.0001.</p>
<p>Study 2 was an open-label study of  9 patients, ages 7 years to 11 years (mean 10 years), with exocrine <span class="product-label-link" type="condition" conceptid="4243784" conceptname="Pancreatic insufficiency">pancreatic insufficiency</span> due to <span class="product-label-link" type="condition" conceptid="441267" conceptname="Cystic fibrosis">cystic fibrosis</span>. The final analysis population was limited to 7 patients who completed both the washout and treatment phases of the study. After a 15 day screening period on individually-titrated doses of ULTRESA not to exceed 2,500 lipase units per kilogram per meal, patients in Study 2 entered a 7-day washout phase (no treatment) before returning to a 12-day treatment phase on the same individually-titrated dose of ULTRESA. The mean daily dose of ULTRESA during the treatment phase was 6,846 lipase units per kilogram body weight per day. All patients consumed a high-fat diet (2 grams of fat per kilogram of body weight per day) during both the washout phase and the treatment phase.
</p>
<p>The mean coefficient of fat absorption (CFA) was determined during the washout phase (no treatment) and during the ULTRESA treatment phase.  Mean CFA was 35% during the washout phase and was 83% during the ULTRESA treatment phase. 
</p>
</div>
<div class="Section" data-sectionCode="34093-5">
<a name="section_15"></a><a name="section-14"></a><p></p>
<h1>15 REFERENCES</h1>
<p class="First">
              1. Borowitz DS, Grand RJ, Durie PR, et al. Use of pancreatic enzyme supplements for patients with <span class="product-label-link" type="condition" conceptid="441267" conceptname="Cystic fibrosis">cystic fibrosis</span> in the context of <span class="product-label-link" type="condition" conceptid="40482055" conceptname="Fibrosing colonopathy">fibrosing colonopathy</span>. <span class="Italics">Journal of Pediatrics. </span>1995; 127: 681-684.</p>
<p>
              2. Borowitz DS, Baker RD, Stallings V. Consensus report on nutrition for pediatric patients with <span class="product-label-link" type="condition" conceptid="441267" conceptname="Cystic fibrosis">cystic fibrosis</span>.<span class="Italics"> Journal of Pediatric Gastroenterology Nutrition. </span>2002 Sep; 35: 246-259.</p>
<p>
              3. Stallings VA, Start LJ, Robinson KA, et al. Evidence-based practice recommendations for nutrition-related management of children and adults with <span class="product-label-link" type="condition" conceptid="441267" conceptname="Cystic fibrosis">cystic fibrosis</span> and <span class="product-label-link" type="condition" conceptid="4243784" conceptname="Pancreatic insufficiency">pancreatic insufficiency</span>: results of a systematic review. <span class="Italics">Journal of the American Dietetic Association</span>. 2008; 108: 832-839.</p>
<p>
              4. Smyth RL, Ashby D, Oâ€™Hea U, et al. <span class="product-label-link" type="condition" conceptid="40482055" conceptname="Fibrosing colonopathy">Fibrosing colonopathy</span> in <span class="product-label-link" type="condition" conceptid="441267" conceptname="Cystic fibrosis">cystic fibrosis</span>: results of a case-control study. <span class="Italics">Lancet. </span>1995; 346: 1247-1251.</p>
<p>
              5. FitzSimmons SC, Burkhart GA, Borowitz DS, et al. High-dose pancreatic-enzyme supplements and <span class="product-label-link" type="condition" conceptid="40482055" conceptname="Fibrosing colonopathy">fibrosing colonopathy</span> in children with <span class="product-label-link" type="condition" conceptid="441267" conceptname="Cystic fibrosis">cystic fibrosis</span>. <span class="Italics">New England</span><span class="Italics"> Journal of Medicine. </span>1997; 336: 1283-1289.</p>
</div>
<div class="Section" data-sectionCode="34069-5">
<a name="section_16"></a><a name="section-15"></a><p></p>
<h1>16 HOW SUPPLIED/STORAGE AND HANDLING</h1>
<p class="First"><span class="Underline">ULTRESA Delayed-Release Capsules</span></p>
<p>4,000 USP units of lipase; 8,000 USP units of protease; 8,000 USP units of amylase</p>
<p>Each ULTRESA capsule is available as a two-piece hypromellose capsule with a flesh opaque cap printed with â€œULTRESAâ€? and blue opaque body printed with â€œ4000â€? that contains light brown, bright, homogeneous micro-tablets of delayed-release pancrelipase supplied in bottles of:</p>
<ul><li>100 capsules (NDC 58914-006-10)</li></ul>
<p><span class="Underline">ULTRESA Delayed-Release Capsules</span></p>
<p></p>
<p>13,800 USP units of lipase; 27,600 USP units of protease; 27,600 USP units of amylase</p>
<p>Each ULTRESA capsule is available as a two-piece gelatin capsule with a white cap printed with â€œ13800ULâ€? and a yellow body printed with â€œAXCAâ€? that contains light brown, bright, homogeneous mini-tablets of delayed-release pancrelipase supplied in bottles of:</p>
<ul><li>100 capsules (NDC 58914-003-10)</li></ul>
<p><span class="Underline">ULTRESA Delayed-Release Capsules</span></p>
<p>20,700 USP units of lipase; 41,400 USP units of protease; 41,400 USP units of amylase</p>
<p>Each ULTRESA capsule is available as a two-piece gelatin capsule with a gray cap printed with â€œ20700ULâ€? and a white body printed with â€œAXCAâ€? that contains light brown, bright, homogeneous mini-tablets of delayed-release pancrelipase supplied in bottles of:</p>
<ul><li>100 capsules (NDC 58914-019-10)</li></ul>
<p><span class="Underline">ULTRESA Delayed-Release Capsules</span></p>
<p>23,000 USP units of lipase; 46,000 USP units of protease; 46,000 USP units of amylase</p>
<p>Each ULTRESA capsule is available as a two-piece gelatin capsule with a light gray cap printed with â€œ23000ULâ€? and a yellow body printed with â€œAXCAâ€? that contains light brown, bright, homogeneous mini-tablets of delayed-release pancrelipase supplied in bottles of:</p>
<ul><li>100 capsules (NDC 58914-005-10)</li></ul>
<p><span class="Bold">Storage and Handling</span></p>
<p>Avoid excessive heat. ULTRESA capsules should be stored in a dry place in the original container. Store at room temperature 20-25Â°C (68-77Â°F). <span class="Underline">After opening, keep the container tightly closed</span> between uses to <span class="Underline">protect from moisture</span>.</p>
<p>ULTRESA is dispensed in bottles containing a desiccant. The desiccant packet should not be eaten or thrown away. The desiccant packet will protect the product from moisture.</p>
<p><span class="Underline">Do not crush ULTRESA</span> delayed-release capsule or the capsule contents.</p>
</div>
<div class="Section" data-sectionCode="34076-0">
<a name="section_17"></a><a name="section-16"></a><p></p>
<h1>17 PATIENT COUNSELING INFORMATION </h1>
<p class="First">See FDA-approved patient labeling (Medication Guide)</p>
<div class="Section" data-sectionCode="42229-5">
<a name="section_17_1"></a><a name="section-16.1"></a><p></p>
<h2>17.1 Dosing and Administration </h2>
<ul><li>Instruct patients and caregivers that ULTRESA should only be taken as directed by their health care provider. Patients should be advised that the total daily dose should not exceed 10,000 lipase units/kg body weight/day unless clinically indicated. This needs to be especially emphasized for patients eating multiple snacks and meals per day. Patients should be informed that if a dose is missed, the next dose should be taken with the next meal or snack as directed. Doses should not be doubled. [see<span class="Italics"> Dosage and Administration (<a href="#section_2">2</a>)</span>]</li></ul>
<ul><li>Instruct patients and caregivers that ULTRESA should always be taken with food. Patients should be advised that ULTRESA delayed-release capsules must not be crushed or chewed as doing so could cause early release of enzymes and/or loss of enzymatic activity and irritation of the oral mucosa. Patients should swallow the intact capsules with adequate amounts of liquid at mealtimes. If necessary, the capsules contents can also be sprinkled on soft acidic foods. [see <span class="Italics">Dosage and Administration (<a href="#section_2">2</a>)</span>]</li></ul>
<ul><li>Any unused portion of capsule contents should be discarded, and not used for subsequent dosing. The remaining exposed contents may lose potency and become less effective. [see <span class="Italics">Dosage and Administration (<a href="#section_2">2</a>)</span>]</li></ul>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section_17_2"></a><a name="section-16.2"></a><p></p>
<h2>17.2 <span class="product-label-link" type="condition" conceptid="40482055" conceptname="Fibrosing colonopathy">Fibrosing Colonopathy</span></h2>
<p class="First">Advise patients and caregivers to follow dosing instructions carefully, as doses of pancreatic enzyme products exceeding 6,000 lipase units/kg of body weight per meal (10,000 lipase units/kg body weight/day)Â have been associated with <span class="product-label-link" type="condition" conceptid="4078069" conceptname="Stenosis of colon">colonic strictures</span> (a rare bowel disorder) in children below the age of 12 years. [see <span class="Italics">Dosage and Administration (<a href="#section_2">2</a>) and Warnings and Precautions (<a href="#section_5_1">5.1</a>)</span>]</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section_17_3"></a><a name="section-16.3"></a><p></p>
<h2>17.3 <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">Allergic Reactions</span></h2>
<p class="First">Advise patients and caregivers to contact their health care provider immediately if <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">allergic reactions</span> to ULTRESA develop.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section_17_4"></a><a name="section-16.4"></a><p></p>
<h2>17.4 Pregnancy and Breast Feeding</h2>
<ul><li>Instruct patients to notify their physician if they are pregnant or are thinking of becoming pregnant during treatment with ULTRESA. [see <span class="Italics">Use in Specific Populations (<a href="#section_8_1">8.1</a>)</span>]</li></ul>
<ul><li>Instruct patients to notify their physician if they are breast feeding or are thinking of breast feeding during treatment with ULTRESA. [see <span class="Italics">Use in Specific Populations (<a href="#section_8_3">8.3</a>)</span>]</li></ul>
<p class="First">
                Marketed by:<br>
                Aptalis Pharma US, Inc<br>
                100 Somerset Corporate Boulevard<br>
                Bridgewater, NJ 08807</p>
<p>
                Manufactured by:<br>
                Aptalis Pharma S.r.L.<br>
                Pessano, Italy 20060</p>
<p>ULTRESA is a registered trademark of Aptalis Pharma US, Inc. or its affiliates.</p>
<p>Â© 2014 APTALIS PHARMA US, INC.</p>
</div>
</div>
<div class="Section" data-sectionCode="42231-1">
<a name="section_18"></a><a name="section-17"></a><p></p>
<h1>MEDICATION GUIDE</h1>
<p class="First"><span class="Bold">ULTRESA<span class="Sup">Â®</span> (ul-tres-a) </span></p>
<p><span class="Bold">(pancrelipase)</span></p>
<p><span class="Bold">delayed-release capsules</span></p>
<p>Read this Medication Guide before you start taking ULTRESA and each time you get a refill. There may be new information. This information does not take the place of talking with your doctor about your medical condition or treatment.</p>
<p><span class="Bold">What is the most important information I should know about ULTRESA?</span></p>
<p>ULTRESA may increase your chance of having a rare bowel disorder called <span class="product-label-link" type="condition" conceptid="40482055" conceptname="Fibrosing colonopathy">fibrosing colonopathy</span>. This condition is serious and may require surgery. The risk of having this condition may be reduced by following the dosing instructions that your doctor gave you.</p>
<p><span class="Bold">Call your doctor right away if you have any unusual or severe:</span></p>
<ul>
<li>stomach area (abdominal) <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span></li>
<li><span class="product-label-link" type="condition" conceptid="442597" conceptname="Swollen abdomen">bloating</span></li>
<li>trouble passing stool (having bowel movements)</li>
<li><span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span>, <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span> or <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span> </li>
</ul>
<p>Take ULTRESA exactly as prescribed by your doctor. Do not take more or less ULTRESA than directed by your doctor.</p>
<p><span class="Bold">What is ULTRESA?</span></p>
<p>ULTRESA is a prescription medicine used to treat people who cannot digest food normally because their pancreas does not make enough enzymes due to <span class="product-label-link" type="condition" conceptid="441267" conceptname="Cystic fibrosis">cystic fibrosis</span> or other conditions.
						</p>
<p>ULTRESA capsules contain a mixture of digestive enzymes including lipases, proteases, and amylases from pig pancreas.</p>
<p><span class="Bold">What should I tell my doctor before taking ULTRESA?</span></p>
<p><span class="Bold">Before you take ULTRESA, tell your doctor about all of your medical conditions, including if you:</span></p>
<ul>
<li>are allergic to pork (pig) products</li>
<li>have a history of intestinal blockage, or <span class="product-label-link" type="condition" conceptid="4050007" conceptname="Scar">scarring</span> or thickening of your bowel wall  (<span class="product-label-link" type="condition" conceptid="40482055" conceptname="Fibrosing colonopathy">fibrosing colonopathy</span>)</li>
<li>have <span class="product-label-link" type="condition" conceptid="440674" conceptname="Gout">gout</span>, kidney disease, or a condition called high blood uric acid (<span class="product-label-link" type="condition" conceptid="4147761" conceptname="Hyperuricemia">hyperuricemia</span>) </li>
<li>have trouble swallowing capsules</li>
<li>have any other medical condition</li>
<li>are pregnant or plan to become pregnant. It is not known if ULTRESA will harm your unborn baby.</li>
<li>are breastfeeding or plan to breastfeed. It is not known if ULTRESA passes into your breast milk. You and your doctor should decide if you will take ULTRESA or breastfeed.</li>
</ul>
<p><span class="Bold">Tell your doctor about all the medicines you take, </span>including prescription and over-the-counter medicines, vitamins, and herbal supplements.</p>
<p>Know the medicines you take. Keep a list of them and show it to your doctor and pharmacist when you get a new medicine.</p>
<p><span class="Bold">How should I take ULTRESA?</span></p>
<ul>
<li><span class="Bold">Take ULTRESA capsules exactly as your doctor tells you.</span></li>
<li>You should not switch ULTRESA with any other pancreatic enzyme product without first talking to your doctor.</li>
<li>Do not take more capsules in a day than the number your doctor tells you to take (total daily dose).</li>
<li>Always take ULTRESA with a meal or snack and plenty of fluid.  If you eat a lot of meals or snacks in a day, be careful not to go over your total daily dose.</li>
<li>Your doctor may change your dose based on the amount of fatty foods you eat or based on your weight.</li>
<li>
<span class="Bold">Do not crush or chew the ULTRESA capsules or their contents, and do not hold the capsule or capsule contents in your mouth. </span>Crushing, chewing or holding the ULTRESA capsules in your mouth may cause irritation in your mouth or change the way ULTRESA works in your body.</li>
</ul>
<p><span class="Bold">Giving ULTRESA to infants</span> (up to 12 months of age):</p>
<ol>
<li>Give ULTRESA right before each feeding of formula or breast milk.</li>
<li>Do not mix ULTRESA capsule contents directly into formula or breast milk.</li>
<li>Open the capsule and sprinkle the contents on a small amount of soft acidic food such as applesauce, pureed bananas or pears. These foods should be the kind found in baby food jars that you buy at the store, or other foods recommended by your doctor. You may also sprinkle the capsule contents directly into your infantâ€™s mouth and immediately give formula or breast milk to ensure your infant has swallowed the medicine completely.</li>
<li>If you sprinkle the ULTRESA on food, give the ULTRESA and food mixture to your infant right away. Do not store ULTRESA that is mixed with food. Throw away any unused portion of capsule contents.</li>
<li>Give your infant enough formula or breast milk to completely swallow the ULTRESA capsule contents or the ULTRESA and food mixture.</li>
<li>Look in your infant's mouth to make sure that all of the medicine has been swallowed.</li>
<li>If you miss giving your infant a dose of ULTRESA, wait and give the prescribed dose of ULTRESA right before the next feeding of formula or breast milk. <span class="Bold">Do not give 2 doses at one time.</span>
</li>
</ol>
<p><span class="Bold">Giving ULTRESA to children and adults:</span></p>
<ol>
<li>You should not divide the capsule contents into small amounts to give small doses of ULTRESA.</li>
<li>Swallow ULTRESA capsules whole and take them with enough liquid to swallow them right away.</li>
<li>If you have trouble swallowing capsules, open the capsule and sprinkle the contents on a small amount of soft acidic food including applesauce or yogurt. Ask your doctor about other foods you can mix with ULTRESA.</li>
<li>If you sprinkle ULTRESA on food, swallow it right after you mix it and drink plenty of water or juice to make sure the medicine is swallowed completely.  Do not store ULTRESA that is mixed with food.  Throw away any unused portion of capsule contents.</li>
<li>If you miss a dose of ULTRESA, wait until your next meal or snack and take your prescribed dose. Take your next dose at your usual time. <span class="Bold">Do not take two doses at one time.</span>
</li>
</ol>
<p><span class="Bold">What are the possible side effects of ULTRESA?</span></p>
<p><span class="Bold">ULTRESA may cause serious side effects, including:</span></p>
<ul>
<li>See <span class="Bold">â€œWhat is the most important information I should know about ULTRESA?â€?</span>
</li>
<li>
<span class="Bold">Irritation of the inside of your mouth. </span>This can happen if ULTRESA is not swallowed completely.</li>
<li>
<span class="Bold">Increase in blood uric acid levels. </span>This may cause worsening of swollen, <span class="product-label-link" type="condition" conceptid="77074" conceptname="Joint pain">painful joints</span> (<span class="product-label-link" type="condition" conceptid="440674" conceptname="Gout">gout</span>) caused by an increase of uric acid levels in your blood..</li>
<li>
<span class="Bold"><span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">Allergic reactions</span>, including </span>trouble breathing, <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">skin rash</span>, <span class="product-label-link" type="condition" conceptid="4302654" conceptname="Itching">itching</span>, or <span class="product-label-link" type="condition" conceptid="44783305" conceptname="Lip swelling">swollen lips</span>. </li>
</ul>
<p> Call your doctor right away if you have any of these symptoms.</p>
<p><span class="Bold">The most common side effects of ULTRESA include: </span></p>
<ul>
<li><span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">headache</span></li>
<li><span class="product-label-link" type="condition" conceptid="26711" conceptname="Chronic pharyngitis">throat pain</span></li>
<li><span class="product-label-link" type="condition" conceptid="318556" conceptname="Epistaxis">nose bleeds</span> </li>
</ul>
<p>
              Other possible side effects:
            </p>
<p>ULTRESA and other pancreatic enzyme products are made from the pancreas of pigs, the same pigs people eat as pork. These pigs may carry viruses.  Although it has never been reported, it may be possible for a person to get a <span class="product-label-link" type="condition" conceptid="440029" conceptname="Viral disease">viral infection</span> from taking pancreatic enzyme products that come from pigs.</p>
<p>Tell your doctor if you have any side effect that bothers you or that does not go away.</p>
<p>These are not all the possible side effects of ULTRESA. For more information, ask your doctor or pharmacist.</p>
<p>Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088.</p>
<p>You may also report side effects to Aptalis Pharma, US Inc. / Forest Laboratories, LLC at 1-800-472-2634.</p>
<p><span class="Bold">How should I store ULTRESA?</span></p>
<ul>
<li>Store ULTRESA at room temperature 68Â°F to 77Â°F (20Â°C to 25Â°C).  Avoid heat. </li>
<li>ULTRESA capsules should be stored in a dry place in the original container.</li>
<li>After opening the bottle, keep it closed tightly between uses to keep your medicine dry (protect it from moisture).</li>
<li>The ULTRESA bottle contains a desiccant packet to help keep your medicine dry (protect it from moisture). <span class="Bold">Do not throw away or eat the desiccant packet.</span>
</li>
</ul>
<p><span class="Bold">Keep ULTRESA and all medicines out of the reach of children.</span></p>
<p><span class="Bold">General information about the safe and effective use of ULTRESA</span></p>
<p>Medicines are sometimes prescribed for purposes other than those listed in a Medication Guide. Do not use ULTRESA for a condition for which it was not prescribed. Do not give ULTRESA to other people to take, even if they have the same symptoms you have. It may harm them.</p>
<p>This Medication Guide summarizes the most important information about ULTRESA. If you would like more information, talk to your doctor. You can ask your doctor or pharmacist for information about ULTRESA that is written for health professionals.</p>
<p>For more information, go to <a href="http://www.ultresa.com">www.ultresa.com</a> or call toll-free 1-800-472-2634.</p>
<p><span class="Bold">What are the ingredients in ULTRESA?</span></p>
<p><span class="Bold">Active ingredient: </span> lipase, protease, amylase.</p>
<p><span class="Bold">Inactive ingredients:</span> colloidal silicon dioxide, croscarmellose sodium, hydrogenated castor oil, hypromellose phthalate, magnesium stearate, microcrystalline cellulose, talc, and triethyl citrate.</p>
<p><span class="Bold">Capsule shell ingredients:</span><br>
				  ULTRESA 4,000 USP units of lipase; 8,000 USP units of protease; 8,000 USP units of amylase contains hypromellose, titanium dioxide, FD&amp;C Blue 1, red iron oxide, and capsule imprint ink.<br></p>
<p>ULTRESA 13,800 USP units of lipase; 27,600 USP units of protease; 27,600 USP units of amylase contains gelatin, titanium dioxide, yellow iron oxide, and capsule imprint ink.</p>
<p>ULTRESA 20,700 USP units of lipase; 41,400 USP units of protease; 41,400 USP units of amylase contains gelatin, titanium dioxide, black iron oxide, and capsule imprint ink.</p>
<p>ULTRESA 23,000 USP units of lipase; 46,000 USP units of protease; 46,000 USP units of amylase contains gelatin, titanium dioxide, yellow iron oxide, black iron oxide, and capsule imprint ink.</p>
<p>The black radial imprinting on the capsule contains Iron oxide black as colorant, shellac, and propylene glycol. It may also contain strong <span class="product-label-link" type="condition" conceptid="4184927" conceptname="Ammonia">ammonia</span> solution, and potassium hydroxide.</p>
<p>This Medication Guide has been approved by the U.S. Food and Drug Administration.</p>
<p><span class="Bold">Marketed by:</span></p>
<p>Aptalis Pharma US, Inc</p>
<p>100 Somerset Corporate Boulevard<br>Bridgewater, NJ 08807</p>
<p><span class="Bold">Manufactured by:</span><br>
            Aptalis Pharma S.r.L.<br>
            Pessano, Italy 20060</p>
<p>Revised: 09/2014</p>
<p>ULTRESAÂ® is a registered trademark of Aptalis Pharma US, Inc. or its affiliates.</p>
<p>Â© 2014 APTALIS PHARMA US, INC.</p>
</div>
<div class="Section" data-sectionCode="51945-4">
<a name="principalPanel"></a><a name="section-18"></a><p></p>
<h1>Principal Display Panel -Package Labels</h1>
<p class="First">Bottle Labels</p>
<p></p>
<p><img alt="Lipase 4,000 USP Bottle" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=73861076-218d-4f8e-872d-0e0690c374a8&amp;name=4000bottle.jpg"></p>
<p><img alt="Lipase 13,800 USP Bottle" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=73861076-218d-4f8e-872d-0e0690c374a8&amp;name=13800bottle.jpg"></p>
<p><img alt="Lipase 20,700 USP Bottle" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=73861076-218d-4f8e-872d-0e0690c374a8&amp;name=20700bottle.jpg"></p>
<p><img alt="Lipase 23,000 USP Bottle" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=73861076-218d-4f8e-872d-0e0690c374a8&amp;name=23000bottle.jpg"></p>
<p>Carton Label</p>
<p><img alt="Carton Label" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=73861076-218d-4f8e-872d-0e0690c374a8&amp;name=carton.jpg"></p>
</div>
</div>
<div class="DataElementsTables">
<table class="contentTablePetite" cellSpacing="0" cellPadding="3" width="100%"><tbody>
<tr><td class="contentTableTitle">
<strong>ULTRESAÂ 		
					</strong><br><span class="contentTableReg">pancrelipase capsule, delayed release</span>
</td></tr>
<tr><td><table width="100%" cellpadding="5" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Information</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Product Type</td>
<td class="formItem">HUMAN PRESCRIPTION DRUG LABEL</td>
<td class="formLabel">Item Code (Source)</td>
<td class="formItem">NDC:58914-006</td>
</tr>
<tr class="formTableRow">
<td width="30%" class="formLabel">Route of Administration</td>
<td class="formItem">ORAL</td>
<td width="30%" class="formLabel">DEA Schedule</td>
<td class="formItem">Â Â Â Â 
							</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="3" class="formHeadingTitle">Active Ingredient/Active Moiety</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Basis of Strength</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">
<strong>PANCRELIPASE LIPASE</strong> (PANCRELIPASE LIPASE) </td>
<td class="formItem">PANCRELIPASE LIPASE</td>
<td class="formItem">4000Â [USP'U]</td>
</tr>
<tr class="formTableRow">
<td class="formItem">
<strong>PANCRELIPASE PROTEASE</strong> (PANCRELIPASE PROTEASE) </td>
<td class="formItem">PANCRELIPASE PROTEASE</td>
<td class="formItem">8000Â [USP'U]</td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">
<strong>PANCRELIPASE AMYLASE</strong> (PANCRELIPASE AMYLASE) </td>
<td class="formItem">PANCRELIPASE AMYLASE</td>
<td class="formItem">8000Â [USP'U]</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="2" class="formHeadingTitle">Inactive Ingredients</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>COLLOIDAL SILICON DIOXIDE</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>CROSCARMELLOSE SODIUM</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>HYDROGENATED CASTOR OIL</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>HYPROMELLOSE PHTHALATE (24% PHTHALATE, 55 CST)</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>MAGNESIUM STEARATE</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>CELLULOSE, MICROCRYSTALLINE</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>TALC</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>TRIETHYL CITRATE</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>TITANIUM DIOXIDE</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>FD&amp;C BLUE NO. 1</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>FERRIC OXIDE RED</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>FERROSOFERRIC OXIDE</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>SHELLAC</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>PROPYLENE GLYCOL</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong><span class="product-label-link" type="condition" conceptid="4184927" conceptname="Ammonia">AMMONIA</span></strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>POTASSIUM HYDROXIDE</strong></td>
<td class="formItem">Â </td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Characteristics</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Color</td>
<td class="formItem">blue (flesh opaque cap and blue opaque body) </td>
<td class="formLabel">Score</td>
<td class="formItem">no score</td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Shape</td>
<td class="formItem">CAPSULE</td>
<td class="formLabel">Size</td>
<td class="formItem">19mm</td>
</tr>
<tr class="formTableRowAlt">
<td class="formLabel">Flavor</td>
<td class="formItem"></td>
<td class="formLabel">Imprint Code</td>
<td class="formItem">ULTRESA;4000</td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Contains</td>
<td class="formItem">Â Â Â Â </td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="5" class="formHeadingTitle">Packaging</td></tr>
<tr>
<th scope="col" width="1" class="formTitle">#</th>
<th scope="col" class="formTitle">Item Code</th>
<th scope="col" class="formTitle">Package Description</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem">NDC:58914-006-10</td>
<td class="formItem">1  in 1 CARTON</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem"></td>
<td class="formItem">100  in 1 BOTTLE</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td class="normalizer"><table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Marketing Information</span></td></tr>
<tr>
<th scope="col" class="formTitle">Marketing Category</th>
<th scope="col" class="formTitle">Application Number or Monograph Citation</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">NDA</td>
<td class="formItem">NDA022222</td>
<td class="formItem">04/01/2015</td>
<td class="formItem"></td>
</tr>
</table></td></tr>
</tbody></table>
<table class="contentTablePetite" cellSpacing="0" cellPadding="3" width="100%"><tbody>
<tr><td class="contentTableTitle">
<strong>ULTRESAÂ 		
					</strong><br><span class="contentTableReg">pancrelipase capsule, delayed release</span>
</td></tr>
<tr><td><table width="100%" cellpadding="5" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Information</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Product Type</td>
<td class="formItem">HUMAN PRESCRIPTION DRUG LABEL</td>
<td class="formLabel">Item Code (Source)</td>
<td class="formItem">NDC:58914-003</td>
</tr>
<tr class="formTableRow">
<td width="30%" class="formLabel">Route of Administration</td>
<td class="formItem">ORAL</td>
<td width="30%" class="formLabel">DEA Schedule</td>
<td class="formItem">Â Â Â Â 
							</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="3" class="formHeadingTitle">Active Ingredient/Active Moiety</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Basis of Strength</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">
<strong>PANCRELIPASE LIPASE</strong> (PANCRELIPASE LIPASE) </td>
<td class="formItem">PANCRELIPASE LIPASE</td>
<td class="formItem">13800Â [USP'U]</td>
</tr>
<tr class="formTableRow">
<td class="formItem">
<strong>PANCRELIPASE PROTEASE</strong> (PANCRELIPASE PROTEASE) </td>
<td class="formItem">PANCRELIPASE PROTEASE</td>
<td class="formItem">27600Â [USP'U]</td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">
<strong>PANCRELIPASE AMYLASE</strong> (PANCRELIPASE AMYLASE) </td>
<td class="formItem">PANCRELIPASE AMYLASE</td>
<td class="formItem">27600Â [USP'U]</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="2" class="formHeadingTitle">Inactive Ingredients</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>COLLOIDAL SILICON DIOXIDE</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>CROSCARMELLOSE SODIUM</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>HYDROGENATED CASTOR OIL</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>HYPROMELLOSE PHTHALATE (24% PHTHALATE, 55 CST)</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>MAGNESIUM STEARATE</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>CELLULOSE, MICROCRYSTALLINE</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>TALC</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>TRIETHYL CITRATE</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>GELATIN</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>FERRIC OXIDE YELLOW</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>TITANIUM DIOXIDE</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>FERROSOFERRIC OXIDE</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>SHELLAC</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>PROPYLENE GLYCOL</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong><span class="product-label-link" type="condition" conceptid="4184927" conceptname="Ammonia">AMMONIA</span></strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>POTASSIUM HYDROXIDE</strong></td>
<td class="formItem">Â </td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Characteristics</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Color</td>
<td class="formItem">yellow (white cap and yellow body) </td>
<td class="formLabel">Score</td>
<td class="formItem">no score</td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Shape</td>
<td class="formItem">CAPSULE</td>
<td class="formLabel">Size</td>
<td class="formItem">19mm</td>
</tr>
<tr class="formTableRowAlt">
<td class="formLabel">Flavor</td>
<td class="formItem"></td>
<td class="formLabel">Imprint Code</td>
<td class="formItem">13800UL;AXCA</td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Contains</td>
<td class="formItem">Â Â Â Â </td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="5" class="formHeadingTitle">Packaging</td></tr>
<tr>
<th scope="col" width="1" class="formTitle">#</th>
<th scope="col" class="formTitle">Item Code</th>
<th scope="col" class="formTitle">Package Description</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem">NDC:58914-003-10</td>
<td class="formItem">1  in 1 CARTON</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem"></td>
<td class="formItem">100  in 1 BOTTLE</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td class="normalizer"><table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Marketing Information</span></td></tr>
<tr>
<th scope="col" class="formTitle">Marketing Category</th>
<th scope="col" class="formTitle">Application Number or Monograph Citation</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">NDA</td>
<td class="formItem">NDA022222</td>
<td class="formItem">03/01/2012</td>
<td class="formItem"></td>
</tr>
</table></td></tr>
</tbody></table>
<table class="contentTablePetite" cellSpacing="0" cellPadding="3" width="100%"><tbody>
<tr><td class="contentTableTitle">
<strong>ULTRESAÂ 		
					</strong><br><span class="contentTableReg">pancrelipase capsule, delayed release</span>
</td></tr>
<tr><td><table width="100%" cellpadding="5" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Information</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Product Type</td>
<td class="formItem">HUMAN PRESCRIPTION DRUG LABEL</td>
<td class="formLabel">Item Code (Source)</td>
<td class="formItem">NDC:58914-019</td>
</tr>
<tr class="formTableRow">
<td width="30%" class="formLabel">Route of Administration</td>
<td class="formItem">ORAL</td>
<td width="30%" class="formLabel">DEA Schedule</td>
<td class="formItem">Â Â Â Â 
							</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="3" class="formHeadingTitle">Active Ingredient/Active Moiety</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Basis of Strength</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">
<strong>PANCRELIPASE LIPASE</strong> (PANCRELIPASE LIPASE) </td>
<td class="formItem">PANCRELIPASE LIPASE</td>
<td class="formItem">20700Â [USP'U]</td>
</tr>
<tr class="formTableRow">
<td class="formItem">
<strong>PANCRELIPASE PROTEASE</strong> (PANCRELIPASE PROTEASE) </td>
<td class="formItem">PANCRELIPASE PROTEASE</td>
<td class="formItem">41400Â [USP'U]</td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">
<strong>PANCRELIPASE AMYLASE</strong> (PANCRELIPASE AMYLASE) </td>
<td class="formItem">PANCRELIPASE AMYLASE</td>
<td class="formItem">41400Â [USP'U]</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="2" class="formHeadingTitle">Inactive Ingredients</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>COLLOIDAL SILICON DIOXIDE</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>CROSCARMELLOSE SODIUM</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>HYDROGENATED CASTOR OIL</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>HYPROMELLOSE PHTHALATE (24% PHTHALATE, 55 CST)</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>MAGNESIUM STEARATE</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>CELLULOSE, MICROCRYSTALLINE</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>TALC</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>TRIETHYL CITRATE</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>GELATIN</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>TITANIUM DIOXIDE</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>FERROSOFERRIC OXIDE</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>SHELLAC</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>PROPYLENE GLYCOL</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong><span class="product-label-link" type="condition" conceptid="4184927" conceptname="Ammonia">AMMONIA</span></strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>POTASSIUM HYDROXIDE</strong></td>
<td class="formItem">Â </td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Characteristics</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Color</td>
<td class="formItem">white (gray cap and white body) </td>
<td class="formLabel">Score</td>
<td class="formItem">no score</td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Shape</td>
<td class="formItem">CAPSULE</td>
<td class="formLabel">Size</td>
<td class="formItem">21mm</td>
</tr>
<tr class="formTableRowAlt">
<td class="formLabel">Flavor</td>
<td class="formItem"></td>
<td class="formLabel">Imprint Code</td>
<td class="formItem">20700UL;AXCA</td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Contains</td>
<td class="formItem">Â Â Â Â </td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="5" class="formHeadingTitle">Packaging</td></tr>
<tr>
<th scope="col" width="1" class="formTitle">#</th>
<th scope="col" class="formTitle">Item Code</th>
<th scope="col" class="formTitle">Package Description</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem">NDC:58914-019-10</td>
<td class="formItem">1  in 1 CARTON</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem"></td>
<td class="formItem">100  in 1 BOTTLE</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td class="normalizer"><table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Marketing Information</span></td></tr>
<tr>
<th scope="col" class="formTitle">Marketing Category</th>
<th scope="col" class="formTitle">Application Number or Monograph Citation</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">NDA</td>
<td class="formItem">NDA022222</td>
<td class="formItem">03/01/2012</td>
<td class="formItem"></td>
</tr>
</table></td></tr>
</tbody></table>
<table class="contentTablePetite" cellSpacing="0" cellPadding="3" width="100%"><tbody>
<tr><td class="contentTableTitle">
<strong>ULTRESAÂ 		
					</strong><br><span class="contentTableReg">pancrelipase capsule, delayed release</span>
</td></tr>
<tr><td><table width="100%" cellpadding="5" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Information</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Product Type</td>
<td class="formItem">HUMAN PRESCRIPTION DRUG LABEL</td>
<td class="formLabel">Item Code (Source)</td>
<td class="formItem">NDC:58914-005</td>
</tr>
<tr class="formTableRow">
<td width="30%" class="formLabel">Route of Administration</td>
<td class="formItem">ORAL</td>
<td width="30%" class="formLabel">DEA Schedule</td>
<td class="formItem">Â Â Â Â 
							</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="3" class="formHeadingTitle">Active Ingredient/Active Moiety</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Basis of Strength</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">
<strong>PANCRELIPASE LIPASE</strong> (PANCRELIPASE LIPASE) </td>
<td class="formItem">PANCRELIPASE LIPASE</td>
<td class="formItem">23000Â [USP'U]</td>
</tr>
<tr class="formTableRow">
<td class="formItem">
<strong>PANCRELIPASE PROTEASE</strong> (PANCRELIPASE PROTEASE) </td>
<td class="formItem">PANCRELIPASE PROTEASE</td>
<td class="formItem">46000Â [USP'U]</td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">
<strong>PANCRELIPASE AMYLASE</strong> (PANCRELIPASE AMYLASE) </td>
<td class="formItem">PANCRELIPASE AMYLASE</td>
<td class="formItem">46000Â [USP'U]</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="2" class="formHeadingTitle">Inactive Ingredients</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>COLLOIDAL SILICON DIOXIDE</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>CROSCARMELLOSE SODIUM</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>HYDROGENATED CASTOR OIL</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>HYPROMELLOSE PHTHALATE (24% PHTHALATE, 55 CST)</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>MAGNESIUM STEARATE</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>CELLULOSE, MICROCRYSTALLINE</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>TALC</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>TRIETHYL CITRATE</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>GELATIN</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>TITANIUM DIOXIDE</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>FERRIC OXIDE YELLOW</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>FERROSOFERRIC OXIDE</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>SHELLAC</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>PROPYLENE GLYCOL</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong><span class="product-label-link" type="condition" conceptid="4184927" conceptname="Ammonia">AMMONIA</span></strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>POTASSIUM HYDROXIDE</strong></td>
<td class="formItem">Â </td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Characteristics</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Color</td>
<td class="formItem">yellow (light gray cap and yellow body) </td>
<td class="formLabel">Score</td>
<td class="formItem">no score</td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Shape</td>
<td class="formItem">CAPSULE</td>
<td class="formLabel">Size</td>
<td class="formItem">21mm</td>
</tr>
<tr class="formTableRowAlt">
<td class="formLabel">Flavor</td>
<td class="formItem"></td>
<td class="formLabel">Imprint Code</td>
<td class="formItem">23000UL;AXCA</td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Contains</td>
<td class="formItem">Â Â Â Â </td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="5" class="formHeadingTitle">Packaging</td></tr>
<tr>
<th scope="col" width="1" class="formTitle">#</th>
<th scope="col" class="formTitle">Item Code</th>
<th scope="col" class="formTitle">Package Description</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem">NDC:58914-005-10</td>
<td class="formItem">1  in 1 CARTON</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem"></td>
<td class="formItem">100  in 1 BOTTLE</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td class="normalizer"><table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Marketing Information</span></td></tr>
<tr>
<th scope="col" class="formTitle">Marketing Category</th>
<th scope="col" class="formTitle">Application Number or Monograph Citation</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">NDA</td>
<td class="formItem">NDA022222</td>
<td class="formItem">03/01/2012</td>
<td class="formItem"></td>
</tr>
</table></td></tr>
</tbody></table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite"><tr><td colspan="4" class="formHeadingReg">
<span class="formHeadingTitle">Labeler -Â </span>Aptalis Pharma US, Inc
							(033555307)
						</td></tr></table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite"><tr><td colspan="4" class="formHeadingReg">
<span class="formHeadingTitle">Registrant -Â </span>Aptalis Pharma US, Inc (033555307)</td></tr></table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Establishment</span></td></tr>
<tr>
<th scope="col" class="formTitle">Name</th>
<th scope="col" class="formTitle">Address</th>
<th scope="col" class="formTitle">ID/FEI</th>
<th scope="col" class="formTitle">Business Operations</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">Aptalis Pharma SRL</td>
<td class="formItem"></td>
<td class="formItem">514114920</td>
<td class="formItem">manufacture(58914-003, 58914-019, 58914-005, 58914-005), analysis(58914-006, 58914-003, 58914-019, 58914-005)</td>
</tr>
</table>
</div>
<p><div class="EffectiveDate">Revised: 9/2014<div class="DocumentMetadata">
<div>
<a href="javascript:toggleMixin();">Document Id: </a>e10091e4-71b9-47bd-a6e1-1b53de27430f</div>
<div>Set id: 73861076-218d-4f8e-872d-0e0690c374a8</div>
<div>Version: 4</div>
<div>Effective Time: 20140930</div>
</div>
</div>Â <div class="DistributorName">Aptalis Pharma US, Inc</div></p>
</body></html>
